THOUSAND OAKS, Calif.--(BUSINESS WIRE)--April 4, 2006--Amgen
(Nasdaq:AMGN), the world´s largest biotechnology company, today
announced plans to report its first quarter financial results on
Tuesday, April 18, 2006 after the close of the financial markets. The
announcement will be followed by a live conference with the investment
community at 2 p.m. Pacific Daylight Time.
Participating in the event from Amgen will be Kevin Sharer,
chairman and chief executive officer, and other members of Amgen´s
senior management team.
Live audio of the conference call will be simultaneously broadcast
over the Internet and will be available to members of the news media,
investors and the general public. The conference call, including the
question and answer session, is expected to last approximately one
The webcast of the conference, as with other selected
presentations regarding developments in Amgen´s business given by
management at certain investor and medical conferences, can be found
on Amgen´s Web site, www.amgen.com, under Investors. Information
regarding presentation times, webcast availability, and webcast links
are noted on Amgen´s Investor Relations Events Calendar. The webcast
will be archived and available for replay for at least seven days
after the event.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science´s promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a broad and deep pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people´s lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks
Dan Whelan, 805-447-4587 (media)
Arvind Sood, 805-447-1060 (investors)